Open
Developing Medicines through Open Science (DMOS)
Supports open science partnerships for preclinical drug development
Last Update: March 4, 2026
Funding available
$ 1,600,000
Timeline
- Open Date : October 1, 2024
Location
Ontario, Canada
Overview
The Developing Medicines through Open Science (DMOS) program provides up to $1,600,000 per project to support preclinical drug development in areas of pharmaceutical market failure, such as rare diseases and antimicrobial resistance. Eligible activities include research projects within Technology Readiness Levels (TRLs) 2-6 that involve at least one Canadian SME and adhere to the open science policy.
/100
Opportunity Score
Moderate potential, but conditions must align.
At a glance
Funding available
Financing goals
- Develop strategic partnerships
- Develop a new product or service
- Conduct research and development activities
Eligible Funding
- Maximum amount : 1,600,000 $
- Up to 50% of project cost
Timeline
- Open Date : October 1, 2024
Eligible candidates
Eligible Industries
- Professional, scientific and technical services
- Health care and social assistance
Location
- Ontario
Legal structures
- Non-profit
- Public or Parapublic institution
- For-profit business
Annual revenue
- All revenue ranges
Organisation size
- All organization sizes
Audience
- Canadians
- Startups
Non-profit candidates
Sector of operation
- Higher Education
- Research
- Other Health Services
- Economic, Social and Community Development
Target groups
- Business owners / entrepreneurs
- Nonprofits / charities
- Academia / students
Revenue structures
- All structures
Scope
- National
Next steps
1
Determine your project
2
Validate your eligibility
Activities funded
- Preclinical research projects developing drug candidates for life-threatening or severely debilitating diseases where pharmaceutical market solutions are lacking (such as orphan or neglected diseases, antimicrobial resistance, and pandemic preparedness).
- Projects aiming to validate drug targets and demonstrate proof of concept for new medicines through open science approaches.
- Collaborative initiatives involving Canadian small and medium-sized enterprises (SMEs) to advance drug candidates from early-stage chemical probes to drugs ready for clinical trial application.
Eligibility
Who is eligible?
- Canadian small and medium-sized enterprises (SMEs) involved in preclinical drug development
- Academic research teams partnering with Canadian SMEs
- Organizations focused on drug development for orphan diseases
- Organizations working on solutions for rare or neglected diseases, pandemic preparedness, or antimicrobial resistance
Eligible expenses
- Project-related expenses that align with the approved research activities.
- Travel expenses for attending project-progress events requested by the program.
- Salaries and staff hours as tracked in submitted timesheets.
- Other costs incurred with prior formal approval for changes to the research project.
Eligible geographic areas
- Canadian companies
Additional information
- The funding process is interactive and applicants may be asked to revise their application during review.
- Conscience charges a 5% administration fee and may retain up to 10% of the claim amount from each reimbursement.
- Grantees are subject to potential audit requirements and must provide additional documentation if requested.
- Selected applicants may be invited to participate in events and networking opportunities organized by Conscience.
Frequently Asked Questions about the Developing Medicines through Open Science (DMOS) Program
Here are answers to the most common questions about the Developing Medicines through Open Science (DMOS). This section explains what the program is, how much funding is available, eligibility requirements, application deadlines, and other important details to help you determine if this grant is right for your business.
What is the Developing Medicines through Open Science (DMOS)?
The Developing Medicines through Open Science (DMOS) program provides up to $1,600,000 per project to support preclinical drug development in areas of pharmaceutical market failure, such as rare diseases and antimicrobial resistance. Eligible activities include research projects within Technology Readiness Levels (TRLs) 2-6 that involve at least one Canadian SME and adhere to the open science policy.
How much funding can be received?
Developing Medicines through Open Science (DMOS) Funds up to 50% of admissible expenses, capped at $1,600,000 per project.
Who is eligible for the Developing Medicines through Open Science (DMOS) program?
To be eligible for the Developing Medicines through Open Science (DMOS) program, you must:
Include at least one Canadian SME in the project
Propose preclinical research in an area of pharmaceutical market failure
Provide proof of matching funds
What expenses are eligible under Developing Medicines through Open Science (DMOS)?
Preclinical research projects developing drug candidates for life-threatening or severely debilitating diseases where pharmaceutical market solutions are lacking (such as orphan or neglected diseases, antimicrobial resistance, and pandemic preparedness).
Projects aiming to validate drug targets and demonstrate proof of concept for new medicines through open science approaches.
Collaborative initiatives involving Canadian small and medium-sized enterprises (SMEs) to advance drug candidates from early-stage chemical probes to drugs ready for clinical trial application.
Where is the Developing Medicines through Open Science (DMOS) available?
The Developing Medicines through Open Science (DMOS) program is available the province of Ontario.
Is the Developing Medicines through Open Science (DMOS) a grant, loan, or tax credit?
Developing Medicines through Open Science (DMOS) is a Partnering and Collaboration
Who are the financial supporters of the Developing Medicines through Open Science (DMOS)?
Developing Medicines through Open Science (DMOS) is funded by Conscience
More programs like this
Expanded Energy Management ProgramMax $250,00050%- XLerate ProgramMax $15,000,00075%
INVEST North Program — Investment — Grow StreamMax $1,000,00050%
